Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic ...

Initiate pivotal studies for NX-5948: Nurix is evaluating NX-5948 in an ongoing Phase 1b clinical trial in adults with relapsed or refractory B-cell malignancies and expects to initiate a suite of ...

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

Learn about Nurix Therapeutics (NRIX) focusing on protein degradation in cancer treatment, with promising early-stage data ...

FDA Grants NX-5948 Fast Track Designation in R/R Waldenström Macroglobulinemia The FDA granted fast track designation to NX-5948, a brain-penetrant, orally bioavailable BTK degrader, on December 19, ...

NX-5948 has received fast track designation for relapsed or refractory Waldenström macroglobulinemia after prior BTK inhibitor therapy. The phase 1a/1b trial of NX-5948 shows a 77.8% objective ...

“Fast Track designation for NX-5948 is an important recognition of the unmet patient need in Waldenstrom’s macroglobulinemia, particularly in the growing number of patients whose cancer has progressed ...